Company news
Protagonist Therapeutics, Inc. news in 2019
Protagonist Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
December 2, 2019
Protagonist Therapeutics Reports Third Quarter 2019 Financial Results
November 5, 2019
Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease
November 5, 2019
Protagonist Therapeutics Secures Debt Facility for up to $50 Million
October 30, 2019
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera
October 29, 2019
Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting
September 30, 2019
Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2
September 24, 2019
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference
September 2, 2019
Protagonist Therapeutics Reports Second Quarter 2019 Financial Results
August 6, 2019
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
July 31, 2019
Protagonist Therapeutics to Present at the BMO 2019 Prescription for Success Healthcare Conference
June 16, 2019
Protagonist Therapeutics Appoints Don Kalkofen as Chief Financial Officer
May 28, 2019